

March 4, 2026

Notice of Submission of Clinical Trial Plan for Domestic Phase I Clinical Trial of OJI-220

Oji Holdings Corporation (CEO: Hiroyuki Isono, Head Office: Chuo-ku, Tokyo) announces that its wholly owned subsidiary, Oji Pharma Co., Ltd. (President: Kotaro Ishikawa, Head Office: Chuo-ku, Tokyo), has submitted a clinical trial plan notification to the Pharmaceuticals and Medical Devices Agency (PMDA) yesterday for OJI-220, which is under development as a preventive agent for blood coagulation during extracorporeal circulation in hemodialysis. This submission is to initiate the Phase I clinical trial (hereinafter referred to as “this clinical trial”).


This trial is a First in Human study, in which OJI-220 will be administered to humans for the first time. The purpose is to evaluate the safety, tolerability, and pharmacokinetics of OJI-220 by administering it to healthy adult males. The trial is scheduled to begin after a 30-day review by the PMDA.

OJI-220 is a novel compound obtained by sulfating hemicellulose, a soluble component derived from forest resources. Non-clinical studies have confirmed that it exhibits anticoagulant activity similar to heparin.

Currently, heparin and related anticoagulants used during hemodialysis are manufactured from animal-derived raw materials, such as pig intestines. However, the supply of heparin is constantly at risk of instability due to factors such as outbreaks of infectious diseases in animals and fluctuations in livestock numbers based on production policies. Additionally, the use of pig-derived heparin may be restricted due to religious or cultural backgrounds. OJI-220, derived from forest resources, is expected to help solve the supply issues associated with heparin and serve as a new option that can also overcome certain religious and cultural challenges.

Oji Group will continue to contribute to society in the medical and healthcare fields, based on its nature-positive management approach.

■ Drug Development Process



Contact

Business Planning Department,
Oji Pharma Co., Ltd.

Phone: +81-3-3520-9888 E-mail: ojipharma-info@oji-gr.com

Public Relations and Investor Relations Department, Corporate Governance Division,

Oji Holdings Corporation <https://www.ojiholdings.co.jp/en/>

Phone: +81-3-3563-4523 E-mail: oji-holdings@oji-gr.com